36 completed, 33 recruiting, 30 unknown, 12 terminated. 58 Phase 2, 48 Phase 1, 13 Not applicable, 12 Phase 3, 5 Early Phase 1.
Follow Advanced Hepatocellular Carcinoma: new trials by email Literature Review of Advanced Hepatocellular Carcinoma trials Research Report on Advanced Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis | Phase 1 / Phase 2 | Recruiting | Devalingam Mahalingam | 59 | 2026-03-30 | 2026-06-25 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment Lenvatinib - Advanced Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | National Cancer Center, Korea | 50 | 2026-02-01 | 2026-01-07 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. PF-08634404, Ipilimumab - Carcinoma, Hepatocellular, Hepatocellular Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 138 | 2025-12-01 | 2026-10-08 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 92 | 2025-11-17 | 2026-10-16 |
| A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma SZ1003 injection - Advanced Hepatocellular Carcinoma | Early Phase 1 | Not yet recruiting | Guangdong ProCapZoom Biosciences Co., Ltd. | 12 | 2025-09-25 | 2025-10-01 |
| A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma BL-B01D1, Lenvatinib, Finotonlimab - Advanced Hepatocellular Carcinoma | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 74 | 2025-06-24 | 2026-06-10 |
| Ligufalimab and Cadonilimab in Advanced Liver Cancers Ligufalimab, Cadonilimab - Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 64 | 2025-02-18 | 2026-02-27 |
| Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma anti-CD19 CAR-T - Advanced Hepatocellular Carcinoma | Phase 1 | Recruiting | Zhejiang University | 12 | 2025-01-10 | 2025-12-15 |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma ALN-BCAT, Pembrolizumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Recruiting | Alnylam Pharmaceuticals | 158 | 2024-12-30 | 2026-06-17 |
| A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) SHR-8068, Adebrelimab, Bevacizumab - Advanced Hepatocellular Carcinoma | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 590 | 2024-10-28 | 2026-09-25 |
| A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients CD-801 - Advanced Hepatocellular Carcinoma | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 37 | 2024-10-12 | 2025-04-24 |
| Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma Ablation, system therapy - Advanced Hepatocellular Carcinoma, Lung Cancer | Recruiting | Sun Yat-sen University | 470 | 2024-10-04 | 2024-12-03 | |
| Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma Early TIPS - Advanced Hepatocellular Carcinoma, Variceal Bleeding | Not applicable | Recruiting | Sun Yat-sen University | 22 | 2024-10-01 | 2024-10-02 |
| dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma dTACE-HAIC - Advanced Hepatocellular Carcinoma, Atezolizumab | Not applicable | Recruiting | Sun Yat-sen University | 27 | 2024-10-01 | 2024-12-03 |
| Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy Oral fecal microbiota transplantation capsules - Advanced Hepatocellular Carcinoma | Phase 2 | Recruiting | Xu Yong, MD | 30 | 2024-09-03 | 2026-09-10 |
Showing 20 of 126. Sign in to see all of them.
Carcinoma, Hepatocellular (39) · Liver Neoplasms (10) · Neoplasms (4) · Carcinoma, Renal Cell (3) · Lung Neoplasms (3) · Melanoma (3) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Medullary (1) · Carcinoma, Transitional Cell (1)
Neoplasms (45) · Neoplasms by Site (45) · Digestive System Diseases (44) · Digestive System Neoplasms (44) · Liver Diseases (43) · Neoplasms by Histologic Type (41) · Neoplasms, Glandular and Epithelial (40) · Adenocarcinoma (39) · Carcinoma (38) · Liver Neoplasms (34) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Blood-Borne Infections (3)
lenvatinib (12) · Bevacizumab (10) · Sorafenib (9) · Specimen Handling (9) · Magnetic Resonance Spectroscopy (8) · atezolizumab (6) · cabozantinib (6) · camrelizumab (6) · durvalumab (6) · Nivolumab (5) · pembrolizumab (5) · sintilimab (4) · tislelizumab (4) · tremelimumab (4) · Disulfides (3)
Sun Yat-sen University (11) · Zhejiang University (6) · Mayo Clinic (3) · Novartis Pharmaceuticals (3) · Amgen (2) · AstraZeneca (2) · CHA University (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Eastern Hepatobiliary Surgery Hospital (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · National Cancer Center, Korea (2) · National Cancer Institute (NCI) (2) · National Taiwan University Hospital (2) · Second Military Medical University (2) · Shanghai Changzheng Hospital (2)
China (62) · United States (32) · South Korea (18) · Taiwan (12) · Japan (9) · Italy (7) · Canada (6) · Hong Kong (6) · Spain (5) · France (4) · Germany (4) · Singapore (4) · United Kingdom (3) · Puerto Rico (2) · Switzerland (2)
Feng Duan, MD (4) · Ming Kuang, Ph.D. (2) · Tingbo Liang (2) · Wei-Fen Xie, M.D. (2) · Abby Siegel, MD, MS (1) · Ai-jun Li, M.D. (1) · Aiping Zhou Zhou, Doctor (1) · Ann Shing Lee, MBChB(CUHK), FHKAM(Rad) (1) · Ann-Lii Cheng, MD, PhD (1) · Annamaria Colao, MD, PhD (1) · Anthony B El-Khoueiry, MD (1)
PMID 10207464, PMID 10517918, PMID 10573522, PMID 10811995, PMID 10984283, PMID 12066229, PMID 12198662, PMID 12540801, PMID 12591191, PMID 12620148, PMID 12759473, PMID 14762851, PMID 14974910, PMID 15246216, PMID 15761078, PMID 16953241, PMID 17589893, PMID 19846955, PMID 20092990, PMID 21859559, PMID 24297682, PMID 24977690, PMID 26071796, PMID 26734580, PMID 28592620, PMID 29506478, PMID 29631810, PMID 30207593, PMID 33392749, PMID 34187739, PMID 34351608, PMID 35454900, PMID 35712486, PMID 35921605, PMID 38463541, PMID 38617599, PMID 39384742, PMID 40128285, PMID 42047833, PMID 42838226, PMID 42847673, PMID 7568806, PMID 7758431, PMID 8213718, PMID 8635123, PMID 8675143, PMID 8709253, PMID 8903411, PMID 8938543, PMID 9438850
2014 (2), P30CA014089 (2), 2015 (1), 2016 (1), 2017 (1), 2023 (1), 2025 (1), P30CA060553 (1), P30CA138292 (1), U10CA180868 (1), UM1CA186690 (1)